Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
VitaK, Maastricht University, Maastricht, the Netherlands.
Am J Kidney Dis. 2015 Mar;65(3):474-83. doi: 10.1053/j.ajkd.2014.09.014. Epub 2014 Nov 12.
Vitamin K modulates calcification by activating calcification inhibitors such as matrix Gla protein (MGP). In kidney transplant recipients, vitamin K insufficiency is common, but implications for long-term outcomes are unclear.
Single-center observational study with a longitudinal design.
SETTING & PARTICIPANTS: 518 stable kidney transplant recipients; 56% men; mean age, 51±12 (SD) years; and a median of 6 (IQR, 3-12) years after kidney transplantation.
Plasma desphosphorylated-uncarboxylated MGP (dp-ucMGP) levels, reflecting vitamin K status.
All-cause mortality and transplant failure.
At inclusion, median dp-ucMGP level was 1,038 (IQR, 733-1,536) pmol/L, with 473 (91%) patients having vitamin K insufficiency (defined as dp-ucMGP>500pmol/L). During a median follow-up of 9.8 (IQR, 8.5-10.2) years, 152 (29%) patients died and 54 (10%) developed transplant failure. Patients in the highest quartile of dp-ucMGP were at considerably higher mortality risk compared with patients in the lowest quartile (HR, 3.10; 95% CI, 1.87-5.12; P for trend<0.001; P for quartile 1 [Q1] vs Q4<0.001). After adjustment for potential confounders, including kidney function and exclusion of patients treated with a vitamin K antagonist, this association remained significant. Patients in the highest quartile also were at higher risk of developing transplant failure (HR, 2.61; 95% CI, 1.22-5.57; P for trend=0.004; P for Q1 vs Q4=0.01), but this association was lost after adjustment for baseline kidney function (HR, 1.20; 95% CI, 0.52-2.75; P for trend=0.6; P for Q1 vs Q4=0.7).
Although MGP exists as various species, only dp-ucMGP was measured. No data were available for vascular calcification as an intermediate end point.
Vitamin K insufficiency, that is, a high circulating level of dp-ucMGP, is highly prevalent in stable kidney transplant recipients and is associated independently with increased risk of mortality. Future studies should address whether vitamin K supplementation may lead to improved outcomes after kidney transplantation.
维生素 K 通过激活钙化抑制剂,如基质 Gla 蛋白(MGP)来调节钙化。在肾移植受者中,维生素 K 不足很常见,但对长期结局的影响尚不清楚。
单中心观察性研究,采用纵向设计。
518 例稳定的肾移植受者;56%为男性;平均年龄 51±12(SD)岁;肾移植后中位数 6(IQR,3-12)年。
血浆去磷酸化非羧化 MGP(dp-ucMGP)水平,反映维生素 K 状态。
全因死亡率和移植失败。
在纳入时,中位 dp-ucMGP 水平为 1038(IQR,733-1536)pmol/L,473(91%)例患者存在维生素 K 不足(定义为 dp-ucMGP>500pmol/L)。在中位随访 9.8(IQR,8.5-10.2)年期间,152 例(29%)患者死亡,54 例(10%)发生移植失败。与最低四分位数相比,dp-ucMGP 最高四分位数患者的死亡率风险明显更高(HR,3.10;95%CI,1.87-5.12;P<0.001;趋势 P 值<0.001;Q1 与 Q4 比较 P 值<0.001)。调整潜在混杂因素后,包括肾功能和排除接受维生素 K 拮抗剂治疗的患者,这种关联仍然显著。dp-ucMGP 最高四分位数患者发生移植失败的风险也更高(HR,2.61;95%CI,1.22-5.57;P<0.001;Q1 与 Q4 比较 P 值<0.001),但调整基线肾功能后,这种关联消失(HR,1.20;95%CI,0.52-2.75;P 趋势=0.6;Q1 与 Q4 比较 P 值=0.7)。
尽管 MGP 存在多种形式,但仅测量了 dp-ucMGP。作为中间终点的血管钙化无数据。
稳定的肾移植受者中,维生素 K 不足(即 dp-ucMGP 循环水平升高)非常普遍,与死亡率升高独立相关。未来的研究应探讨维生素 K 补充是否可能改善肾移植后的结局。